Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Jun 1;60(2):150-7.
doi: 10.1097/QAI.0b013e318251aedd.

A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa

Anisa Mosam  1 , Fahmida Shaik, Thomas S Uldrick, Tonya Esterhuizen, Gerald H Friedland, David T Scadden, Jamila Aboobaker, Hoosen M Coovadia
Affiliations
Randomized Controlled Trial

A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa

Anisa Mosam et al. J Acquir Immune Defic Syndr. .

Abstract

Background: The optimal approach to HIV-associated Kaposi sarcoma (HIV-KS) in sub-Saharan Africa is unknown. With large-scale rollout of highly active antiretroviral therapy (HAART) in South Africa, we hypothesized that survival in HIV-KS would improve and administration of chemotherapy in addition to HAART would be feasible and improve KS-specific outcomes.

Methods: We conducted a randomized, controlled, open-label trial with intention-to-treat analysis. Treatment-naive patients from King Edward VIII Hospital, Durban, South Africa, a public-sector tertiary referral center, with HIV-KS, but no symptomatic visceral disease or fungating lesions requiring urgent chemotherapy, were randomized to HAART alone or HAART and chemotherapy (CXT). HAART arm received stavudine, lamivudine, and nevirapine (Triomune; CXT arm received Triomune plus bleomycin, doxorubicin, and vincristine every 3 weeks. When bleomycin, doxorubicin, and vincristine were not available, oral etoposide (50-100 mg for 1-21 days of a 28-day cycle) was substituted. Primary outcome was overall KS response using AIDS Clinical Trial Group criteria 12 months after HAART initiation. Secondary comparisons included time to response, progression-free survival, overall survival, adverse events, HIV control, CD4 reconstitution, adherence, and quality of life.

Results: Fifty-nine subjects were randomized to HAART and 53 to CXT; 12-month overall KS response was 39% in the HAART arm and 66% in the CXT arm (difference, 27%; 95% confidence interval, 9%-43%; P = 0.005). At 12 months, 77% were alive (no survival difference between arms; P = 0.49), 82% had HIV viral load <50 copies per milliliter without difference between the arms (P = 0.47); CD4 counts and quality-of-life measures improved in all patients.

Conclusions: HAART with chemotherapy produced higher overall KS response over 12 months, whereas HAART alone provided similar improvement in survival and select measures of morbidity. In Africa, with high prevalence of HIV and human herpes virus-8 and limited resources, HAART alone provides important benefit in patients with HIV-KS.

PubMed Disclaimer

Conflict of interest statement

No other conflicts reported.

Figures

Figure 1
Figure 1. Patient Flow Chart: screening, randomization, follow-up events, and analysis
Figure 2
Figure 2. Progression-free Survival, Time to Response, and Overall Survival
a) Progression-free survival: Kaplan-Meier analysis, hazard ratio for progression in HAART plus chemotherapy (CXT) arm compared to HAART alone arm = 0.52 (95% CI = 0.31, 0.88, log-rank test). b) Time to partial or complete response: based on three-monthly evaluations, patients censored (hatch marks) at time of death or loss to follow-up. Time to response rate ratio HAART arm compared to HAART plus chemotherapy (CXT) arm 2.8 (95% CI 1.7, 4.4, Mantel-Haenszel rate ratio) c) Overall survival by arm: Kaplan-Meier analysis, CXT = HAART plus chemotherapy Difference between arms not significant (p=0.49, log-rank test), also not significant after correcting for TIS risk factors (p=0.33, Cox regression). d) Overall survival by number (0-3) of modified ACTG TIS risk factors, (I1 = CD4 less than 100 cells/mL): Kaplan-Meier analysis, multivariate Cox regression including modified ACTG risk factors effectively risk-stratified patients (p<0.01).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1999;21(1):S34–41. - PubMed
    1. Mosam A, Carrara H, Shaik F, et al. Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983-2006) Int J STD AIDS. 2009 Aug;20(8):553–556. - PubMed
    1. Dedicoat M, Vaithilingum M, Newton R. Treatment of Kaposi's sarcoma in HIV-1 infected individuals with emphasis on resource poor settings. Cochrane Database Syst Rev. 2003;(3):CD003256. - PubMed
    1. Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine. AIDS. 2000;14(8):987–993. - PubMed
    1. Cattelan AM, Calabro ML, De Rossi A, et al. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. Int J Oncol. 2005 Sep;27(3):779–785. - PubMed

Publication types